Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Comparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing.

Wood HM, Foster JM, Taylor M, Tinkler-Hundal E, Togneri FS, Wojtowicz P, Oumie A, Spink KG, Brew F, Quirke P.

BMC Med Genomics. 2017 Mar 18;10(1):17. doi: 10.1186/s12920-017-0254-5.

2.

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA.

Togneri FS, Ward DG, Foster JM, Devall AJ, Wojtowicz P, Alyas S, Vasques FR, Oumie A, James ND, Cheng KK, Zeegers MP, Deshmukh N, O'Sullivan B, Taniere P, Spink KG, McMullan DJ, Griffiths M, Bryan RT.

Eur J Hum Genet. 2016 Aug;24(8):1167-74. doi: 10.1038/ejhg.2015.281. Epub 2016 Jan 13.

3.

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P.

J Pathol. 2016 Mar;238(4):562-70. doi: 10.1002/path.4679. Epub 2016 Jan 29.

4.

Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling.

Foster JM, Oumie A, Togneri FS, Vasques FR, Hau D, Taylor M, Tinkler-Hundal E, Southward K, Medlow P, McGreeghan-Crosby K, Halfpenny I, McMullan DJ, Quirke P, Keating KE, Griffiths M, Spink KG, Brew F.

BMC Med Genomics. 2015 Feb 18;8:5. doi: 10.1186/s12920-015-0079-z.

5.

Relevance of systems pharmacology in drug discovery.

Cucurull-Sanchez L, Spink KG, Moschos SA.

Drug Discov Today. 2012 Jul;17(13-14):665-70. doi: 10.1016/j.drudis.2012.01.015. Epub 2012 Jan 25.

PMID:
22405899
6.

Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.

Moschos SA, Frick M, Taylor B, Turnpenny P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, Weber M, Lazari O, Perez-Tosar L, Fancy SA, Lapthorn C, Green MX, Evans S, Selby M, Jones G, Jones L, Kearney S, Mechiche H, Gikunju D, Subramanian R, Uhlmann E, Jurk M, Vollmer J, Ciaramella G, Yeadon M.

Mol Ther. 2011 Dec;19(12):2163-8. doi: 10.1038/mt.2011.206. Epub 2011 Oct 4.

7.

Measuring the action of CPP-siRNA conjugates in the lung.

Moschos SA, Spink KG, Lindsay MA.

Methods Mol Biol. 2011;683:417-29. doi: 10.1007/978-1-60761-919-2_30.

PMID:
21053147
8.

Improved expression of secreted and membrane-targeted proteins in insect cells.

Hitchman RB, Possee RD, Siaterli E, Richards KS, Clayton AJ, Bird LE, Owens RJ, Carpentier DC, King FL, Danquah JO, Spink KG, King LA.

Biotechnol Appl Biochem. 2010 Jun 21;56(3):85-93. doi: 10.1042/BA20090130.

PMID:
20441568
9.

The importance of XRCC2 in RAD51-related DNA damage repair.

Tambini CE, Spink KG, Ross CJ, Hill MA, Thacker J.

DNA Repair (Amst). 2010 May 4;9(5):517-25. doi: 10.1016/j.dnarep.2010.01.016. Epub 2010 Feb 26.

PMID:
20189471
10.

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J.

Respir Res. 2006 Jan 19;7:9.

11.

The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2.

Braybrooke JP, Spink KG, Thacker J, Hickson ID.

J Biol Chem. 2000 Sep 15;275(37):29100-6.

12.

Sequence-specific binding of Taz1p dimers to fission yeast telomeric DNA.

Spink KG, Evans RJ, Chambers A.

Nucleic Acids Res. 2000 Jan 15;28(2):527-33.

13.

In vivo analysis of functional regions within yeast Rap1p.

Graham IR, Haw RA, Spink KG, Halden KA, Chambers A.

Mol Cell Biol. 1999 Nov;19(11):7481-90.

Supplemental Content

Loading ...
Support Center